Upon oral administration of active pharmaceutical ingredients, achieving adequate absorption for therapeutic effect remains a key challenge for the majority of pipeline drug candidates.1 This is attributed to poor water solubility of hydrophobic and often crystalline small drug molecules. Amorphous solid dispersions (ASDs) have emerged as viable nanomaterials to overcome intrinsic solubility limitations by supersaturating the drug in solution.2 However, preventing reprecipitation over pharmaceutically-relevant time scales mandates nanocarriers that can effectively stabilize amorphized drug molecules. Here, we employ a directed design approach to build libraries of tailored polymers as ASD excipients around the chemical structures of antiseizure and antiandrogen drugs, phenytoin and nilutamide, respectively. High-throughput synthesis and screening tools aided in the development of robust controlled delivery systems that maintained elevated drug concentrations and enhanced oral bioavailability metrics above reported studies to date.3.
|Original language||English (US)|
|Title of host publication||Society for Biomaterials Annual Meeting and Exposition 2019|
|Subtitle of host publication||The Pinnacle of Biomaterials Innovation and Excellence - Transactions of the 42nd Annual Meeting|
|Publisher||Society for Biomaterials|
|Number of pages||1|
|State||Published - 2019|
|Event||42nd Society for Biomaterials Annual Meeting and Exposition 2019: The Pinnacle of Biomaterials Innovation and Excellence - Seattle, United States|
Duration: Apr 3 2019 → Apr 6 2019
|Name||Transactions of the Annual Meeting of the Society for Biomaterials and the Annual International Biomaterials Symposium|
|Conference||42nd Society for Biomaterials Annual Meeting and Exposition 2019: The Pinnacle of Biomaterials Innovation and Excellence|
|Period||4/3/19 → 4/6/19|
Bibliographical notePublisher Copyright:
© 2019 Omnipress - All rights reserved.
- Amorphous Solid Dispersions
- Oral Drug Delivery